Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record.

Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma

Open access
Nakaoku, Takashi, Tsuta, Koji, Ichikawa, Hitoshi, Shiraishi, Kouya, Sakamoto, Hiromi, Enari, Masato, Furuta, Koh, Shimada, Yoko, Ogiwara, Hideaki, Watanabe, Shun-ichi, Nokihara, Hiroshi, Yasuda, Kazuki, Hiramoto, Masaki, Nammo, Takao, Ishigame, Teruhide, Schetter, Aaron J., Okayama, Hirokazu, Harris, Curtis C., Kim, Young Hak, Mishima, Michiaki, Yokota, Jun, Yoshida, Teruhiko, Kohno, Takashi · 2014 · Clinical Cancer Research

Abstract

Purpose: To identify druggable oncogenic fusions in invasive mucinous adenocarcinoma (IMA) of the lung, a malignant type of lung adenocarcinoma in which KRAS mutations frequently occur. Experimental Design: From an IMA cohort of 90 cases, consisting of 56 cases (62%) with KRAS mutations and 34 cases without (38%), we conducted whole-transcriptome sequencing of 32 IMAs, including 27 cases without KRAS mutations. We used the sequencing data to identify gene fusions, and then performed functional analyses of the fusion gene products. Results: We identified oncogenic fusions that occurred mutually exclusively with KRAS mutations: CD74-NRG1, SLC3A2-NRG1, EZR-ERBB4, TRIM24-BRAF, and KIAA1468-RET. NRG1 fusions were present in 17.6% (6/34) of KRAS-negative IMAs. The CD74-NRG1 fusion activated HER2:HER3 signaling, whereas the EZR-ERBB4 and TRIM24-BRAF fusions constitutively activated the ERBB4 and BRAF kinases, respectively. Signaling pathway activation and fusion-induced anchorage-independent growth/tumorigenicity of NIH3T3 cells expressing these fusions were suppressed by tyrosine kinase inhibitors approved for clinical use. Conclusions: Oncogenic fusions act as driver mutations in IMAs without KRAS mutations, and thus represent promising therapeutic targets for the treatment of such IMAs. Clin Cancer Res; 20(12); 3087–93. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0107

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 206

Metadata

Authors
Nakaoku, T., Tsuta, K., Ichikawa, H., Shiraishi, K., Sakamoto, H., Enari, M., Furuta, K., Shimada, Y., Ogiwara, H., Watanabe, S.-I., Nokihara, H., Yasuda, K., Hiramoto, M., Nammo, T., Ishigame, T., Schetter, A. J., Okayama, H., Harris, C. C., Kim, Y. H., Mishima, M., Yokota, J., Yoshida, T., & Kohno, T.
Venue
Clinical Cancer Research
Published
2014-06-12
Volume
20
Issue
12
Pages
3087-3093
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2155888371
Cited by
206
References
0
FWCI
15.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0107
The paper
Nakaoku, T., Tsuta, K., Ichikawa, H., Shiraishi, K., Sakamoto, H., Enari, M., Furuta, K., Shimada, Y., Ogiwara, H., Watanabe, S.-I., Nokihara, H., Yasuda, K., Hiramoto, M., Nammo, T., Ishigame, T., Schetter, A. J., Okayama, H., Harris, C. C., Kim, Y. H., . . . Kohno, T. (2014). Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0107

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.